FILANA THERAPEUTICS, INC.
For the period ended Dec 31, 2025. Filed Mar 12, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 12, 2026
FLNA$0.49+8.7%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
(In thousands, except share and par value data)
| December 31, | ||
|---|---|---|
| 2025 | 2024 | |
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | $95,502 | $128,574 |
| Prepaid expenses and other current assets | 2,207 | 7,958 |
| Total current assets | 97,709 | 136,532 |
| Property and equipment, net | 20,646 | 21,001 |
| Total assets | $118,355 | $157,533 |
| LIABILITIES AND STOCKHOLDERS' EQUITY | ||
| Current liabilities: | ||
| Accounts payable and other accrued expenses | $41,647 | $7,654 |
| Accrued development expense | 364 | 2,440 |
| Accrued compensation and benefits | 1,625 | 1,357 |
| Other current liabilities | 198 | 299 |
| Total current liabilities | 43,834 | 11,750 |
| Other non-current liabilities | 118 | 79 |
| Total liabilities | 43,952 | 11,829 |
| Commitments and contingencies (Notes 10, 11 and 12) | ||
| Stockholders' equity: | ||
| Preferred stock, $0.001 par value; 10,000,000 shares authorized, none issued and outstanding | — | — |
| Common stock, $0.001 par value; 120,000,000 shares authorized; 48,307,896 and 48,203,179 shares issued and outstanding at December 31, 2025 and 2024, respectively | 48 | 48 |
| Additional paid-in capital | 570,439 | 550,767 |
| Accumulated deficit | (496,084) | (405,111) |
| Total stockholders' equity | 74,403 | 145,704 |
| Total liabilities and stockholders' equity | $118,355 | $157,533 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.